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Objectives. The aim of this study was to compare complications 
in a large cohort of patients undergoing pectoral cardioverter- 
defibrillator implantation with a subcutaneous or submuscular 
approach. 
Background. Pectoral placement of implantable eardioverter- 
defibrillator (ICD) pulse generators is now routine because of 
downsizing of these devices. Subcutaneous implantation has been 
advocated by some because it is a simple surgical procedure 
comparable to pacemaker insertion. Others have favored submus- 
cular insertion to avoid wound complications. These surgical 
approaches have not been compared previously. 
Methods. The subjects for this study were 1,000 consecutive 
patients receiving a Medtronic Jewel ICD at 93 centers worldwide. 
Cumulative follow-up for all patients was 633.7 patient-years, with 
64.9% of patients followed up for >6 months. The complications 
evaluated were erosion, pocket hematoma, seroma, wound infec- 
tion, dehiscence, device migration, lead fracture and dislodgment. 
Results. Subcutaneous implantation was performed in 604 
patients and submuscular implantation in the remaining 396. The 
median procedural times were shorter for subcutaneous implan- 
tation (p = 0.014). In addition, the cumulative percentage of 
patients free from erosion was greater for subcutaneous implan- 
tations (p = 0.03, 100% vs. 99.1% at 6 months). However, lead 
dislodgment was more common with subcutaneous implantations 
(p = 0.019, 2.3% vs. 0.5% at 6 months) and occurred primarily 
during the first month postoperatively. Overall, there were no 
significant differences in cumulative freedom from complications 
between groups (4.1% vs. 2.5%, p = 0.1836). 
Conclusions. Subcutaneous pectoral implantation of this ICD 
can be performed safely and has a low complication rate. This 
approach requires a simple surgical procedure and, compared 
with the submuscular approach, is associated with shorter proce- 
dure times and comparable overall complication rates. However, 
early follow.up is important in view of the increased lead dislodg- 
ment rate. 
(J Am Coil Cardiol 1996;28:1278-82) 
The implantable cardioverter-defibrillator (ICD) has become 
standard therapy for the treatment of life-threatening ventric- 
ular arrhythmias (1-3). Over the past several years, the im- 
plantation technique has evolved considerably. With the de- 
velopment of integrated lead systems and the improvement of 
shock waveforms, nonthoracotomy and now transvenous im- 
plantation have become standard (4-9). Such approaches 
reduce the morbidity, mortality and costs of ICD placement 
compared with traditional epicardial techniques (10-13). 
More recently, sufficient downsizing of pulse generators has 
been achieved to allow pectoral implantation. This downsiz- 
ing further simplifies the implantation procedure by avoid- 
ing the need for tunneling to the abdomen. In addition, 
defibrillation efficacy is enhanced because the pectoral pulse 
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generator can serve as part of the defibrillation pathway 
(14,1S). 
Although transvenous pectoral implantation has rapidly 
become the standard technique for initial ICD placement, 
controversy persists regarding the best surgical approach. 
Placement of the pulse generator in the subcutaneous ti sue of 
the upper chest, superficial to the pectoralis muscles, isfeasible 
and allows implantation comparable topermanent pacemaker 
insertion (16,17). This approach permits wide dissemination f 
this technology and most likely reduces costs by minimizing the 
need for general anesthesia and the use of operating rooms. 
However, the present generation of ICD pulse generators i
significantly larger (68 to 83 cm 3) than present pacemakers and 
comparable in size to early pacemakers that were subject o 
frequent wound complications, including erosion (18,19). This 
observation has led some to advocate routine submuscular 
placement, which is a more complicated procedure (20-22). 
This approach involves transecting the pectoralis major muscle 
or the use of multiple incisions to tunnel below the muscle. No 
direct comparisons of the subcutaneous and submuscular 
implantation techniques have been performed. Accordingly, 
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the present study evaluated 1,000 consecutive patients under- 
going initial pectoral ICD placement u ilizing one or the other 
of these approaches. 
Methods 
The subjects for this study were obtained from the data base 
of Medtronic, Inc. and include 1,000 consecutive patients 
receiving aJewel ICD (models 7219D, 7219B and 7202D pulse 
generators) implanted in the pectoral position. These devices 
have a pulse generator shell with a weight of 132 g and a 
volume of 83 cm 3. This study was restricted to all initial 
implantations that were performed between September 1993 
and March 1995 at 93 centers worldwide during the investiga- 
tional phase of this device. Written informed consent was 
obtained from each patient, and the study was approved by the 
institutional review boards of the participating centers. Demo- 
graphic and implantation data were obtained from standard- 
ized forms completed and forwarded to the sponsor for 
inclusion in the data bank. Implantation time was defined as the 
time from the initial incision to final wound closing. 
A variety of lead combinations were used to meet the 
implantation criteria of a defibrillation threshold -<24 J re- 
quired by investigational protocol. All patients received aright 
ventricular lead (model 6936) for bipolar sensing, pacing and 
shock therapy. The other leads used were a superior vena cava 
or coronary sinus coil (model 6933) and a subcutaneous patch 
(model 6963). The choice of lead system, pulse generator and 
implantation technique (i.e., subcutaneous v . submuscular) 
was at the discretion of the implanting physician. All pulse 
generators and leads were manufactured byMedtronic, Inc. 
After device implantation, patients were evaluated at 1 
month, 3 months and every 3 months thereafter. At each 
follow-up visit, standardized forms were completed. For study 
purposes, acomplication was defined prospectively as an event 
identified by the investigator that required invasive surgical 
intervention. Complications evaluated were erosion, pocket 
hematoma, pocket seroma, wound infection, wound dehis- 
cence, device migration, lead fracture and lead dislodgment. 
Data analysis. Comparisons were made between the sub- 
cutaneous and submuscular groups. Data are shown as mean 
value __ SD, unless otherwise indicated. For continuous vari- 
ables, the Wilcoxon rank-sum nonparametric test was used 
because of skewness of the distribution of the variables. For 
discrete variables, the continuity-adjusted chi-square test was 
used. Kaplan-Meier methods were used to estimate the cumu- 
lative percentage of patients free from complications over 
time. Comparisons between the cumulative vent-free curves 
were made using the log-rank statistic. Stepwise Cox regression 
methods were used to examine the association of risk factors 
with the time to first occurrence of complications. A p value 
<0.05 was considered statistically significant. 
Results 
Patients. The clinical characteristics of the patients are 
shown in Table 1. The subcutaneous and submuscular imptan- 
Table 1. Clinical Characteristics of 1,000 Study Patients 
Subcutaneous Submuscular 
Implantation Implantation p 
(n - 604) (n = 396) Value 
Age (yr) 60.5 ± 12.1 60.2 _+ 13.5 0.758 
Male 82.0 82.8 0.787 
Ejection fraction 33.6 ± 13.5 33.0 + 13.9 0.400 
Coronal3' artery' disease 71.7 69.4 0.473 
Congestive heart failure 22.8 20.7 0,471 
Previous cardiac surgery 33.9 36.4 0.473 
History. of sudden death 37.9 39.4 0.686 
Data presented are mean value = SD or percent of patients. 
tation groups were well matched, and there were no significant 
differences in any of the clinical variables evaluated. 
ICD implantation. Of the 1,000 patients who underwent 
implantation atthe 93 centers, subcutaneous implantation was 
performed in604 patients (60.4%), whereas the remaining 396 
(39.6%) underwent submuscular implantation. At 27 centers 
(29%), only subcutaneous implantations were performed, 
which accounted for 30% (178) of all such procedures. Con- 
versely, at 23 centers (24.7%), only submuscular procedures 
were performed, accounting for 23.5% (93) of all submuscular 
procedures. The remaining 43 centers performed both subcu- 
taneous and submuscular implantations and contributed 729 
(72.9%) of the total cohort evaluated. 
A variety of lead systems were used in this study. All 
patients had a right ventricular lead for sensing, pacing and 
shock therapy. The most common lead configuration used was 
a two-lead right ventricular/superior vena cava system. This 
configuration was used in 785 patients (78.5%). Three-lead 
systems were used in 75 (12.5%) of subcutaneous implanta- 
tions and 65 (16.5%) of submuscular implantations (p = 
0.091). The three-lead system included a subcutaneous patch 
in 89% of patients (124 of 140), whereas three coils were used 
in the remaining 11% (16 of 140) of patients. 
Procedural and body habitus characteristics are presented 
in Table 2. Patients undergoing subcutaneous implantation 
were significantly heavier (82.6 _+ 16.3 kg vs. 79.8 _+ 17.3 kg, 
p = 0.0053) and had a larger body mass index (27.1 +_ 5.2 vs. 
26.1 _+ 5.1, p = 0.0018) than those undergoing a submuscular 
approach. There were no significant differences in patient 
height. 
Procedural implantation times were 113 _+ 57 rain for 
subcutaneous implants and 120 _+ 57 min for submuscular 
Table 2. Procedural Variables 
Subcutaneous Submuscular 
Implantation Implantation p 
(mean +_ SD) (mean _+ SD) Value 
Procedural time (rain) 113 ± 57 120 ± 57 0.015 
Weight (kg) 82.6 _+ 16.3 79.8 _+ 17.3 0.005 
Height (cm) 174.7 ± 9.6 174.4 + 10.2 0.833 
Body mass index 27.1 ± 5.2 26.1 + 5.1 0.002 
1280 GOLD ET AL. JACC Vol. 28, No. 5 
PECTORAL ICD COMPLICATIONS November 1, 1996:1278-82 
100 
98 
96 
~ 94 
92 
90 
+ .. 
- Submuscular 
~- ~ ~ Subcutaneous 
3 6 9 12 i5 
MONTHS 
N at risk 
Submuscular 396 309 242 171 62 15 
Subcutaneous 604 492 395 263 114 28 
Figure 1. Product-limit estimates of the free- 
dom from a pocket-related complication. Cu- 
mulative percentage of patients without com- 
plications i shown for the two groups, p -- 
0.639 for between-group comparisons. 
implants. Median implantation times were significantly shorter 
with the subcutaneous technique (95 vs. 110 rain, p = 0.014). 
As expected, the median implantation time for three-lead 
systems was longer than for two-lead systems (140 vs. 92 rain, 
p < 0.001). To assess whether the longer procedural times 
associated with submuscular implantations were due to the 
slightly higher frequency of patch placement, he two-lead 
systems in the groups were compared. In patients with two- 
lead transvenous lead systems, median procedural times were 
still shorter with the subcutaneous technique (90 vs. 105 rain, 
p = 0.026). 
Pocket complications. For evaluation of complications, cu- 
mulative patient follow-up for all patients was 633.7 patient- 
years, with 64.9% of patients followed up for ->6 months. 
Comparisons of six-pocket related complications were per- 
formed: skin erosion, pocket hematoma nd seroma, wound 
infection and dehiscence and device migration. Only the 
incidence of skin erosion differed between groups with more 
erosions (three vs. none) observed with submuscular implan- 
tation. These three erosions occurred 0.5, 0.6 and 5.5 months 
after implantation. The cumulative percentage ofpatients free 
from erosion differed between groups (p = 0.03), with esti- 
mates at 6 months of 100% for subcutaneous implants and 
99.1% for submuscular implants. It is noteworthy that only two 
serious wound infections (0.2%) developed in this cohort of 
patients, both of which occurred after subcutaneous implanta- 
tion. 
The overall risk of experiencing any pocket-related compli- 
cation was compared for the two groups. As shown in Figure 1, 
there were no significant differences inthe cumulative percent- 
age of patients free from complication during any period of 
follow-up (p = 0.639). At 6 months, complication-free survival 
was 98.1% for the subcutaneous group and 97.6% for the 
submuscular group. 
Analysis of clinical risk factors indicated that only patient 
age was associated with pocket complications (p = 0.038). The 
risk of a complications decreases by -3.5% for each 1-year 
increase in age. Body weight or size did not correlate with 
overall pocket complications. 
Lead complieations. Lead complications occurred more 
commonly in the subcutaneous group. Dislodgments were 
noted in 15 patients in this group and was primarily due to 
right ventricular lead dislodgment, which occurred in 14 pa- 
tients (2.3%). In contrast, only two dislodgments (0.5%) 
developed in the submuscular group, both of which also 
involved the right ventricular lead. The vast majority of 
dislodgments in the subcutaneous group occurred early in the 
first postoperative month. Subsequently, only occasional dis- 
lodgments were noted in both groups. Lead fractures occurred 
infrequently, with three fractures after subcutaneous implan- 
tation and one after submuscular implantation. Thus, there 
were a total of 18 lead complications (3.0%) in the subcuta- 
neous group and 3 (0.8%) in the submuscular g oup. The time 
course of any lead complication (dislodgment or fracture) is 
shown in Figure 2, demonstrating the lower complication rate 
with the submuscular approach (p = 0.018). Estimated free- 
dom at 6 months from a lead complication is 99.3% for 
submuscular implants and 96.9% for subcutaneous implants. 
Risk factor analysis revealed that only a subcutaneous ap- 
proach was associated with an increased risk of any lead 
complication. Neither the number of implantations at a center 
nor the time period of this clinical trial (i.e., early vs. late) was 
associated with increased islodgments, uggesting that they 
were not due to inexperience with implantation. 
When the risk of any complication was analyzed, the higher 
risk of wound complications in the submuscular group tended 
to offset the higher risk of dislodgment in the subcutaneous 
group. Consequently, the overall cumulative freedom from 
complications did not differ between groups (p = 0.1836). The 
only clinical factor associated with overall complications was a 
history of coronary artery disease (p = 0.047). Patients with 
coronary artery disease have about half the risk of experiencing 
complications. 
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Figure 2. Product-limit estimates offreedom 
from a lead-related complication. Cumulative 
percentage of patients without complications 
is shown for the two groups, p = 0.018 for 
between-group comparisons. 
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Discussion 
With the downsizing of ICD pulse generators and the 
development of active can lead systems, pectoral implantation 
has become standard for initial ICD placement. However, the 
optimal pectoral surgical technique has not been established. 
The major finding of the present study of 1,000 consecutive 
patients is that both subcutaneous and submuscular implanta- 
tion techniques are associated with comparable overall com- 
plication rates, but a shorter procedural time is achieved with 
the subcutaneous approach. 
Comparison with previous studies. Previous studies of 
small groups of patients have established that subcutaneous or 
subpectoral placement of modern ICD pulse generators and 
lead systems is feasible, but no previous comparative studies 
have been published. The simplicity of the pectoral approach 
has been emphasized (16,17) and may result in reduced 
operating room and general anesthesia requirements. In addi- 
tion, the simpler surgical approach would, with appropriate 
training in electrophysiology, permit implantation by those 
who implant permanent pacemakers. The submuscular ap- 
proach has been advocated by others (20-22) to reduce the 
morbidity, associated with ICD pulse generators, which are 
significantly larger than modern pacemakers. Older generation 
pacemakers of comparable size to ICD pulse generators had a 
significant risk of erosions and other pocket complications 
(18,19). However, differences in pulse generator shape and 
patient characteristics makes extrapolation of these results to 
ICD implants difficult. 
Complications. The increased erosion rate for submuscu- 
lar implantation was surprising. However, this finding must be 
interpreted with caution because only three erosions were 
observed, all within 6 months of implantation. It is possible 
that these erosions were due to a selection bias because 
patients undergoing submuscular implantation weighed less 
and had a smaller body surface area. Probably more important 
is the lack of erosions noted in the subcutaneous group despite 
follow-up data for 604 patients. The overall incidence of 
pocket complications was low and did not differ between the 
two implantation techniques. Of note, with the sample size 
evaluated, this study had a power of 86% to detect a 6% 
difference in complication rates at 1 year. 
Lead dislodgment was more common with subcutaneous 
implantation and predominately involved the right ventricular 
active fixation lead. The dislodgment rate observed (2.3%) was 
within the range reported previously for similar leads tunneled 
to an abdominal pocket (5,8,23,24). Dislodgment problems in 
the past have been attributed to inadequate l ad anchoring in 
the pectoral region (5,25). Dislodgments were unlikely to be 
due to inexperience with implantation because these events 
were not related to the number of implantations at a center 
and did not preferentially occur early in the study. Explana- 
tions for the different dislodgment rates include the possibility 
that the submuscular pulse generator position better stabilized 
the lead; that better anchoring technique was used with 
submuscular implants; or that the relatively heavy weight and 
movement of the pulse generator in the subcutaneous position 
contributed to lead instability. These possibilities cannot be 
differentiated from the present data. 
The infection rate in this series was very low (0.2%). 
Previously, infection rates of 1.3% to 2.7% were reported 
(12,26) from other large multicenter t ials of nonthoracotomy 
ICD implantation i  the abdomen. These findings support he 
notion that the higher infection rates consistently noted with 
ICD compared with pacemaker implantation are due to the 
use of an abdominal pocket. 
Limitations of the study. The present study must be inter- 
preted in light of certain methodologic limitations. The choice 
of implantation technique was not randomized or controlled 
and is thus subject o bias. Although the two groups were well 
matched clinically, patients in the subcutaneous group weighed 
on average 2.8 kg more than those in the submuscular g oup. 
This difference suggests that some subjects of small body 
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habitus may have been excluded from subcutaneous implanta- 
tion. However, the very large sample size with >600 patient- 
years of follow-up and the observation that 72.9% of patients 
were from centers that performed both techniques indicate 
that these results are most likely representative of clinical 
practice. Moreover, body size did not correlate with complica- 
tions. 
A second limitation is that long term follow-up is limited, 
particularly >1 year. Accordingly, it is possible that other 
complications will be noted after several years of observation. 
However, with follow-up _>6 months or more available for 649 
patients, accurate estimates of complications during this time 
frame can be ascertained. 
Conclusions. This study demonstrates that subcutaneous 
pectoral implantation of an ICD system with an 83-cm 2 pulse 
generator can be performed with a low rate of complications. 
This approach requires a simple surgical procedure and is 
associated with shorter procedural times and comparable 
overall complication rates compared with the submuscular 
approach. However, careful attention to anchoring techniques 
and close, early follow-up is important in view of the 2.3% rate 
of lead dislodgment hat occurred primarily during the first 
month after implantation. More long-term follow-up is re- 
quired to assess more accurately other chronic complications, 
such as those associated with pulse generator eplacement as 
well as late erosions and lead fractures. 
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